Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
Roy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, Stephanie Lustgarten, Kathleen E Squires, William A Meyer 3rd, Edward P Acosta, Bruce R Schackman, Christopher D Pilcher, Robert L Murphy, William E Maher, Mallory D Witt, Richard C Reichman, Sally Snyder, Karin L Klingman, Daniel R Kuritzkes, AIDS Clinical Trials Group Study A5095 Team, Roy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, Stephanie Lustgarten, Kathleen E Squires, William A Meyer 3rd, Edward P Acosta, Bruce R Schackman, Christopher D Pilcher, Robert L Murphy, William E Maher, Mallory D Witt, Richard C Reichman, Sally Snyder, Karin L Klingman, Daniel R Kuritzkes, AIDS Clinical Trials Group Study A5095 Team
Abstract
Background: Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, but data from direct comparisons are limited.
Methods: This randomized, double-blind study involved three antiretroviral regimens for the initial treatment of subjects infected with HIV-1: zidovudine-lamivudine-abacavir, zidovudine-lamivudine plus efavirenz, and zidovudine-lamivudine-abacavir plus efavirenz.
Results: We enrolled a total of 1147 subjects with a mean baseline HIV-1 RNA level of 4.85 log10 (71,434) copies per milliliter and a mean CD4 cell count of 238 per cubic millimeter were enrolled. A scheduled review by the data and safety monitoring board with the use of prespecified stopping boundaries led to a recommendation to stop the triple-nucleoside group and to present the results in the triple-nucleoside group in comparison with pooled data from the efavirenz groups. After a median follow-up of 32 weeks, 82 of 382 subjects in the triple-nucleoside group (21 percent) and 85 of 765 of those in the combined efavirenz groups (11 percent) had virologic failure; the time to virologic failure was significantly shorter in the triple-nucleoside group (P<0.001). This difference was observed regardless of the pretreatment HIV-1 RNA stratum (at least 100,000 copies per milliliter or below this level; P< or =0.001 for both comparisons). Changes in the CD4 cell count and the incidence of grade 3 or grade 4 adverse events did not differ significantly between the groups.
Conclusions: In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides.
Copyright 2004 Massachusetts Medical Society
Source: PubMed